Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Roche wins FDA approval for first PTEN-loss companion diagnostic in prostate cancer

The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer

OM Pharma to unveil major real-world evidence breakthrough on Broncho-Vaxom at EAACI

The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies

Granules India elevates Ananda Babu Doppalapudi as GM and Head Quality for Vizag API Unit

Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility

Neuland to set up $20m process development facility in Hyderabad

New facility will open by October 2026 and house 500 process development specialists

Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026

The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services

Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push

Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing

Arihant Innochem launches state-of-the-art research & innovation centre in Navi Mumbai

The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments

Leprosy elimination drive intensifies as Indian govt pushes high-burden states toward zero transmission goal

Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts